Is the latest sales price of the generic drug Sotolaxib (AMG510) reliable?
Sotorasiib (AMG510) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy. As an oral small molecule targeted inhibitor, sotoraxib can selectively bind and inhibit the KRAS G12C mutation, blocking its abnormal activation of signaling pathways, thereby slowing down tumor growth and spread. Clinical trials showed that it showed significant anti-tumor activity in patients with KRAS G12C mutated non-small cell lung cancer and was well tolerated.

With the recognition of the efficacy of sotorasiib, some pharmaceutical companies have begun to try to produce generic drugs. At present, in addition to the original research manufacturer Amgen of the United States, Lucius of Laos, Daxiong Pharmaceutical, Everest Pharmaceutical of Bangladesh, etc. are also manufacturers of generic drugs of Sotorasibu. These generic drug manufacturers strictly follow relevant production standards and regulatory requirements during the production process to ensure that the quality, safety and efficacy of the generic drugs are as close as possible to the original drugs. The pharmaceutical ingredients of the generic drugs produced by these manufacturers are basically the same as those of the original drugs sold overseas, but there may be differences in price, specifications, etc.
It is critical for patients and healthcare organizations to understand and stay on top of the latest drug pricing developments. It is understood that the specifications produced by Lucius Pharmaceutical Factory in Laosthe price of 120mg*56 tablets per box is more than 1,000 yuan, that of Daxiong Pharmaceutical is more than 2,000 yuan per box, and Bangladesh Everest Pharmaceutical the price per box is more than 4,000 yuan, (prices may fluctuate due to exchange rate effects). For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)